Jun 18, 2019 13:32 JST

Source: Eisai

Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130

Derived From Total Synthesis of Halichondrin Found in Joint Research Between Eisai and Harvard University Scientists, Published in Scientific Reports

TOKYO, Jun 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that a joint research group including scientists from Eisai and Professor Yoshito Kishi's group of Harvard University has achieved a total synthesis and obtained results of nonclinical studies of the novel compound, E7130, derived from total synthesis of halichondrin. These results have been published in Scientific Reports, a scientific journal of Nature. Currently a Phase I study to investigate E7130 in solid tumor is underway in Japan.

Halichondrins, which was isolated from the marine sponge Halichondria okadai in 1986, was known for their outstanding antitumor activity in mice, however the supply from natural sources were limited. Furthermore, the very complicated chemical structure has prevented drug discovery and development based on intact halichondrins. The joint research group strictly controlled 31 asymmetric carbons and achieved a total synthesis of E7130, on a >10 g scale with >99.8% purity under GMP (good manufacturing practice) conditions.

The joint research team also demonstrated that E7130 is not only a novel microtubule dynamics inhibitor but can also increase intratumoral CD31-positive endothelial cells (vascular remodeling activity) and reduce alpha-SMA (smooth muscle actin)-positive cancer-associated fibroblasts (anti-CAF effect), which are important constituents of the tumor microenvironment and may be involved in the malignant transformation of cancers in nonclinical in vivo studies.

According to these unique effects, E7130 augments the effect of antitumor treatments in nonclinical studies. Overall, our work demonstrates that a total synthesis can address the issue of limited material supply in drug discovery and development even for complex natural products.

"In 1992, it was unthinkable to synthesize a gram-quantity of a halichondrin," said Yoshito Kishi, Morris Loeb Professor of Chemistry, Emeritus, in the Department of Chemistry and Chemical Biology at Harvard University, said "but three years ago we proposed it to Eisai. Organic synthesis has advanced to that level, even with molecular complexity that was untouchable several years ago. We are very delighted to see our basic chemistry discoveries have now made it possible to synthesize this compound at large scale."

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. We will maximize the potential of halichondrins by adding E7130 project to two investigational projects of Eisai's eribulin platform; MORAb-202 (antibody-drug conjugate with eribulin as the payload) and liposomal formulation of eribulin, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

*Harvard has exclusively licensed the intellectual property associated with this research project to Eisai for the commercial development of therapeutics.

About E7130

E7130 is a next-generation agent improving tumor microenvironment, which has been developed by a joint research with Eisai and Harvard University. E7130 is derived from total synthesis of halichondrin, a natural product isolated from the marine sponge Halichondria okadai. E7130 is believed to improve tumor microenvironment by unique action for potential effect on immune activation by releasing hypoxia and suppressing interaction between cancer cells and stroma. A Phase I study to investigate E7130 in solid tumor is currently underway in Japan.

About Eisai
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Public Relations Department,
Eisai Co., Ltd.
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
June 02 2020 10:05 JST
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29 2020 14:54 JST
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29 2020 10:31 JST
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 18 2020 12:33 JST
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
May 14 2020 08:22 JST
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine
April 27 2020 16:26 JST
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
April 01 2020 15:23 JST
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)
March 26 2020 16:01 JST
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20
March 25 2020 08:38 JST
Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health)
March 23 2020 10:53 JST
More Press release >>

Latest Press Release

More Latest Release >>